Kevin Bitterman
InvestorPartner at Atlas Venture
Cambridge, Massachusetts
Writes $10M – $50M checks · typically $25M
About
Kevin Bitterman invests in and helps build companies that turn scientific research into new medicines. He was the founding CEO of Editas Medicine, Morphic Therapeutic (acquired by Lilly), and Visterra (acquired by Otsuka), and joined Atlas Venture in 2017 after serving as a partner on the healthcare team at Polaris Partners since 2004. He holds a BA in biology from Rutgers University and a PhD in genetics from Harvard Medical School.
Invests in
Biotech
Experience
- Atlas VenturePartnercurrent2017 — presentCambridge, MA
- Judo BioBoard of Directorscurrent2022 — presentCambridge, Massachusetts, United States
- Remix TherapeuticsBoard of Directorscurrent2019 — presentCambridge, Massachusetts, United States
- nChroma BioBoard of Directorscurrent2020 — presentCambridge, Massachusetts, United States
- Kinaset TherapeuticsBoard of Directorscurrent2020 — presentBoston, Massachusetts, United States
- Disc MedicineBoard Of Directorscurrent2017 — presentCambridge, MA
- Isabella Stewart Gardner MuseumMember Board of Trusteescurrent2017 — presentBoston, Massachusetts, United States
- Mariana OncologyBoard of Directors2021 — 2024Cambridge, Massachusetts, United States
- New England Venture Capital AssociationBoard Member2013 — 2023Greater Boston Area
- Akero TherapeuticsBoard of Directors2018 — 2021Cambridge, MA
- Navitor PharmaceuticalsBoard of Directors2017 — 2020Cambridge, MA
- Editas MedicineBoard of Directors2014 — 2018Cambridge, MA
- Editas MedicineFounding CEO2013 — 2014Cambridge, MA
- Morphic TherapeuticBoard of Directors2015 — 2017Waltham, MA
- Morphic TherapeuticFounding CEO2014 — 2015Greater Boston Area
- Vets First ChoiceBoard of Directors2012 — 2017
- Neuronetics, Inc.Board of Directors2011 — 2017
- Polaris PartnersPartner2004 — 2017Greater Boston Area
- Kala PharmaceuticalsBoard of Directors2009 — 2017
- Taris BiomedicalBoard of Directors2008 — 2017
Education
- Harvard Medical SchoolPh.D., Genetics1999 — 2004
- Rutgers UniversityBA, Biology1995 — 1999
Skills & more
+12 more
Cell BiologyStart-upsImmunologyVaccinesOncologyInfectious DiseasesDrug DevelopmentBiomarkersPharmaceutical IndustryFDARegulatory AffairsBiochemistryFrom Kevin's professional profile.
Same school
Also attended Harvard Medical School113
+ 107 more
Also attended Rutgers University86
+ 80 more
Shared employers
Also worked at nChroma Bio1
Also worked at Morphic Therapeutic4
Also worked at Neuronetics, Inc.1
Also worked at Polaris Partners32
+ 26 more
Deals · 9
Renasant BioBoard seat
via Atlas Venture · filed Jul 2025 · $30M raise
Gro BiosciencesBoard seat
via Atlas Venture · filed Jul 2024 · $60.4M raise
Chroma Medicine, Inc.Board seat
via Atlas Venture · filed Sep 2023 · $135M raise
Navitor PharmaceuticalsBoard seat
via Atlas Venture · filed May 2020 · $20.2M raise
Akero Therapeutics, Inc.Board seat
via Atlas Venture · filed Dec 2018 · $45.5M raise
Morphic Holding, Inc.Board seat
via Atlas Venture · filed Jul 2016 · $51.5M raise
KALA BIOBoard seat
via Atlas Venture · filed Aug 2015 · $7M raise
Direct Vet MarketingBoard seat
via Atlas Venture · filed Jul 2015 · $52.3M raise
NeuroneticsBoard seat
via Atlas Venture · filed May 2015 · $34.3M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Atlas Venture
Network1
Investors connected to Kevin in public investor directories — a warm-intro map.


.png)



























